

12 September 2024

ASX Announcement

Resignation of Director – Dr Richard Treagus

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) advises that Dr Richard Treagus has resigned his position as a Non-Executive Director of Firebrick Pharma Ltd, effective from 30 September, 2024.

Richard has been a director of Firebrick since June 2022 but he has now decided to focus his time on his other Board roles and business commitments.

The Board would like to thank Richard for his positive contributions over the past two years.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator focused on developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has successfully developed a PVP-I nasal spray (Nasodine® Nasal Spray) and filed international trademarks and multiple patents on the product. The Company has also completed six clinical trials that have affirmed the product's safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Firebrick is now commercialising Nasodine in international markets, with the product already launched in the United States and Singapore.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com